MELANOMA CRITICAL DEBATES - PART 5 ppt

... 19 95; 51 : 57 0–83. 15 Herd RM, Cooper EJ, Hunter JA, et al. Cutaneous malignant melanoma: publicity, screening clinics and survival — the Edinburgh experience 1982–90. Br J Dermatol 19 95; 132: 56 3–70. 16 ... depth distribution of subsequent melanomas [56 58 ]. There are no randomized tri- als of alternative types of follow-up surveillance in high-risk groups. The value of screening...

Ngày tải lên: 09/08/2014, 15:20

... published 2002 Library of Congress Cataloging-in-Publication Data Melanoma: Critical Debates /edited by J. A. Newton Bishop, M. Gore. p. cm. ISBN 0-6 3 2-0 57 7 2-6 1. Melanoma. I. Bishop, J. A. Newton (Julia ... tan year- round are at reduced risk for developing melanoma (OR=0 .5, 95% CI= 0.3–0.9). It is likely that sun-sensitive women are not in this category, as they 8 CHAP...

Ngày tải lên: 09/08/2014, 15:20

... one-third of those hereditary melanoma families contain- ing three or more affected first- or second-degree relatives show inheritance of MANAGING HIGH RISK MELANOMA PATIENTS 71 6 658 35 38 58 ... RJH. Photosensitisation of guanine-specific DNA damage by 2-phenylbenzimidazole and the sunscreen agent 2-phenyl- benzimidazole -5 - sulfonic acid. Chem Res Toxicol 1999; 12: 38– 45. ized by...

Ngày tải lên: 09/08/2014, 15:20

... 9: 251 5. 53 Lattanzi SC, Tosteson T, Chertoff J et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: a 5 year follow-up. Melanoma Res 19 95; 5: 3 65 9. 54 ... vincristine with two dose schedules of 5- ( 3,3-dimethyl-1-triazino) imidazole 4- carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 19 75; 35: 36...

Ngày tải lên: 09/08/2014, 15:20

... UVR susceptibility 53 –4 melanocortin 1 receptor (MC1R) gene 50 –2, 55 –6 melanoma susceptibility and 54 – 5 studies 55 –6 murine genetics 56 regional node relapse 150 – 65 management 150 –60 elective lymph ... 198–200, 199 high-dose 199 low-dose 199–200 trials in stage II 200–1 g-interferon 197, 233, 234, 243 interleukins IL-2 1 95, 197, 222, 238, 243 IL-4 243 IL-10 243 IL-12 243...

Ngày tải lên: 09/08/2014, 15:20

... 1978–83 52 3 /50 5 1.8 (1.2–2.7) ≠ Elwoood & Canada 1979–81 369/369 1.10 (0. 75 1.62) - Gallagher [ 45] Holman et al. [46] Australia 1980–81 50 7 /50 7 1.1 (0.71–1.60) - Holly et al. [47] USA 1981–86 452 /930 ... 116/2 35 0.48 (0.34–0.71) Ø Arranz et al. [52 ] Autier et al. [53 ] Europe 1991–92 418/438 1 .50 (1.09–2.06) ≠ Wolf et al. [54 ] Austria 1993–94 193/319 3 .5 (1.8–6....

Ngày tải lên: 09/08/2014, 15:20

... investigation 5 Does the patient (because of a high-risk profile) need regular follow-up? If so, refer to pigmented lesion clinic Part 2: Diagnosis, Screening and Prevention Melanoma: Critical Debates ... for the regular follow-up of selected high-risk individuals re- sults in thinner melanomas being diagnosed, as concluded from a Dutch study on high-risk patients from melanoma- pro...

Ngày tải lên: 09/08/2014, 15:20

... emphasize 051 0 15 20 25 30 35 40 45 50 55 60 Time (months) Proportion disease-free .4 .1 .2 .3 .5 .6 .7 .8 .9 1.0 Disease-free survival (a) 051 0 15 20 25 30 35 40 45 50 55 60 Time (months) .1 .2 .3 .4 .5 .6 .7 .8 .9 >.99 Overall ... of 2- uoro-2-deoxyglucose (FDG)-PET scanning was re- ported for detection of melanoma metastases [33,34]. Although access to PET is at pr...

Ngày tải lên: 09/08/2014, 15:20

... 20 Dummer et al. [50 ] c.i.v. +DTIC 850 mg/m 2 57 25 NR IL-2 ± IFN-a ± chemotherapy Richards et al. [51 ] b.+ IFN-a+CDDP 74 57 5 > 10 +DTIC+BCNU+tamoxifen Khayat et al. [52 ] c.i.v. +IFN-a+CDDP ±tamoxifen ... DR13 MAGE-4A 55 11 22 MAGE-6 [63] 89 ? ? MAGE-12 89 ? ? MAGE-C1 [36] 37 53 BAGE 22 Cw1601 GAGE [63] 24 Cw6 LAGE [28] 50 SSX-2 [30] 43 NY-ESO-1 [29] 20–40 A2, A31 DAM [27] A2...

Ngày tải lên: 09/08/2014, 15:20

... pro-drug gene therapy system has utilized an Escherichia coli cytosine deaminase gene transfer followed by systemic administration of 5- fluorocytosine ( 5- FC) which yields 5- uorouracil ( 5- FU) ... adenovirus, dL- 152 0, which replicates in p53-deficient cells but not in normal cells, there- fore having the general property of being cancer-specific [13]. This virus, now referred to as ON...

Ngày tải lên: 09/08/2014, 15:20